TY - JOUR
T1 - The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma
T2 - Results from a randomized phase iii study in JGOG3017/GCIG
AU - Kondo, Eiji
AU - Tabata, Tsutomu
AU - Suzuki, Nao
AU - Aoki, Daisuke
AU - Yahata, Hideaki
AU - Kotera, Yoshio
AU - Tokuyama, Osamu
AU - Fujiwara, Keiichi
AU - Kimura, Eizo
AU - Terauchi, Fumitoshi
AU - Sumi, Toshiyuki
AU - Okamoto, Aikou
AU - Yaegashi, Nobuo
AU - Enomoto, Takayuki
AU - Sugiyama, Toru
N1 - Funding Information:
K.E., T.T., S.N., Y.H., K.Y., T.F., S.T., Y.N., and S.T. have nothing to conflict of interest. Dr. Aoki (A.D.) reports personal fees from Daiichi Sankyo Co., Ltd., Yakulut Honsha Co., Ltd., and Nippon Kayaku Co., Ltd., for the outside the submitted work. Dr. Fujiwara (F.K.) reports personal fees from Daiichi-Sankyo, grants and personal fees from Yakult during the conduct of the study. Also, he/she has grants from Kaken, Shionogi, GSK, Lilly, Immunogen, Oncotherapy, and Regeneron; personal fees from Nihon Kayaku, Novartis, Kyowahakko Kirin, Janssen, Daiichi Sankyo, and Mochida; or both (grants and personal fees) form Astra Zeneca, Pfizer, Eisai, MSD, Taiho, Zeria, and Chugai for the outside the submitted work. Dr. Okamoto (O.A.) reports personal fees and other from AstraZeneca for lecture fee; personal fees and other (scholarship) from Chugai; other (scholarship) from MSD; grants from Kaken, Mochida, Kissei, and Pfizer during the conduct of the study. Dr. Enomoto (E.T.) reports personal fees from AstraZeneca, personal fees and other from Chugai for the outside the submitted work.
PY - 2020
Y1 - 2020
N2 - Objective: In this study we sought to investigate the clinical factors that affect post-progression survival (PPS) in patients with recurrent or persistent clear cell carcinoma (CCC). We utilized the JGOG3017/Gynecological Cancer InterGroup data to compare paclitaxel plus carboplatin (TC) and irinotecan plus cisplatin (CPT-P) in the treatment of stages I to IV CCC. Methods: We enrolled 166 patients with recurrent or persistent CCC and assessed the impact of variables, including platinum sensitivity, treatment arm, crossover chemotherapy, primary stage, residual tumor at primary surgery, performance status, ethnicity, and tumor reduction surgery at recurrence on the median of PPS in patients with recurrent or persistent CCC. Results: A total of 77 patients received TC, and 89 patients received CPT-P. The median PPS for patients with platinum-resistant disease was 10.9 months, compared with 18.8 months for patients with platinum-sensitive disease (hazard ratio [HR]=1.88; 95% confidence interval [CI]=1.30–2.72; log-rank p<0.001). In the multivariate analysis, the platinum sensitivity (resistant vs. sensitivity; HR=1.60; p=0.027) and primary stage (p=0.009) were identified as independent predictors of prognosis factors for PPS in recurrent or persistent CCC. Conclusions: Our findings revealed that platinum sensitivity and primary stage are clinical factors that significantly affect PPS in patients with recurrent or persistent CCC as well as other histologic subtypes of ovarian cancer. PPS in patients with recurrent CCC should establish the basis for future clinical trials in this population.
AB - Objective: In this study we sought to investigate the clinical factors that affect post-progression survival (PPS) in patients with recurrent or persistent clear cell carcinoma (CCC). We utilized the JGOG3017/Gynecological Cancer InterGroup data to compare paclitaxel plus carboplatin (TC) and irinotecan plus cisplatin (CPT-P) in the treatment of stages I to IV CCC. Methods: We enrolled 166 patients with recurrent or persistent CCC and assessed the impact of variables, including platinum sensitivity, treatment arm, crossover chemotherapy, primary stage, residual tumor at primary surgery, performance status, ethnicity, and tumor reduction surgery at recurrence on the median of PPS in patients with recurrent or persistent CCC. Results: A total of 77 patients received TC, and 89 patients received CPT-P. The median PPS for patients with platinum-resistant disease was 10.9 months, compared with 18.8 months for patients with platinum-sensitive disease (hazard ratio [HR]=1.88; 95% confidence interval [CI]=1.30–2.72; log-rank p<0.001). In the multivariate analysis, the platinum sensitivity (resistant vs. sensitivity; HR=1.60; p=0.027) and primary stage (p=0.009) were identified as independent predictors of prognosis factors for PPS in recurrent or persistent CCC. Conclusions: Our findings revealed that platinum sensitivity and primary stage are clinical factors that significantly affect PPS in patients with recurrent or persistent CCC as well as other histologic subtypes of ovarian cancer. PPS in patients with recurrent CCC should establish the basis for future clinical trials in this population.
KW - Ovarian Cancer
KW - Platinum
KW - Recurrence
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85093097215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85093097215&partnerID=8YFLogxK
U2 - 10.3802/jgo.2020.31.e94
DO - 10.3802/jgo.2020.31.e94
M3 - Article
C2 - 33078599
AN - SCOPUS:85093097215
VL - 31
SP - 1
EP - 12
JO - Journal of Gynecologic Oncology
JF - Journal of Gynecologic Oncology
SN - 2005-0380
IS - 6
M1 - e94
ER -